smoking

If lifetime tobacco consumption were banned among young people currently aged 14 to 18, 1,200,000 lung cancer deaths worldwide could be prevented in the future, according to a study with Spanish involvement published in the journal The Lancet Public Health. The greatest impact would occur in low- and middle-income countries, but in higher-income regions, more than 60% of lung cancer deaths in that age group would also be avoided.

A clinical trial in Finland has compared the effectiveness of nicotine-containing e-cigarettes and varenicline tablets for smoking cessation. The study, which included 458 participants, found no difference between the two strategies at six months. However, after one year, only varenicline was found to be clearly more effective than placebo. The results are published in the journal JAMA Internal Medicine.  

A journalistic investigation by The Investigative Desk (Netherlands) and The BMJ (UK) concludes that tobacco industry-funded studies continue to appear in the most cited medical journals. The team of journalists found hundreds of links in the PubMed database between the medical and pharmaceutical subsidiaries of the big tobacco companies - Philip Morris International, Altria, British American Tobacco, Imperial Brands and Japan Tobacco International - and published medical research. In addition, the research revealed that of 40 journals - the 10 most cited in general medicine and another 30 in areas affected by smoking - only eight had policies prohibiting studies funded in whole or in part by the tobacco industry. 

E-cigarettes, vapes, pods, mods... The popularity of these devices continues to grow, especially among young people. According to a Spanish survey, more than half of the adolescents aged 14 to 18 have used them at some point. Vaping control varies from country to country: in Spain, vaping products have been regulated since 2017 and the new anti-smoking plan aims to equate their legislation to that of tobacco, while the United States imposes fewer restrictions. In this brief guide, we explain what is known and not known on controversial issues such as the safety of electronic cigarettes, their risks or whether they are useful to quit tobacco.

This Friday, the Interterritorial Council of the National Health System approved the Comprehensive Plan for the Prevention and Control of Smoking (PIT). The document, which incorporates 147 proposals from the autonomous communities, has not achieved consensus among all of them.
 

An international team of researchers has examined the epigenetic effects of tobacco and e-cigarettes over time in more than 3,500 samples. Their results indicate that e-cigarettes can also cause changes associated with an increased risk of cancer even shortly after starting to use them. They publish the study in the journal Cancer Research. 

E-cigarettes combined with traditional therapies are more effective for smoking cessation than regular therapies alone, says a study conducted in Switzerland and published in the New England Journal of Medicine. The study involved two groups of about 600 participants each. At a 6-month control visit, 59.6% of the members of the e-cigarette group had not smoked tobacco in the previous week, compared to 38.5% in the control group.

A study has analysed more than 100 environmental factors and their impact on the immune response. After studying about a thousand volunteers, its conclusions are that smoking is the factor that causes the most alterations in defences. While some changes are transient, others may remain for years after quitting. The results are published in the journal Nature.

In pregnant women, neither regular use of electronic cigarettes nor nicotine replacement therapy is associated with unfavorable effects, according to a trial involving 1,140 pregnant smokers in England and Scotland. The authors analyzed the association between nicotine consumption by the two routes - vaping and nicotine patches - with parameters including infant birth weight, miscarriages, premature births and respiratory symptoms in the mother. The research is published in the scientific journal Addiction.

Un estudio ha estimado las muertes por cáncer que se producirán en la Unión Europea y el Reino Unido en 2023. Comparándolas con las observadas en 2018, estiman que se reducirán en un 6,5 % en hombres y un 3,7 % en mujeres de forma global. Sin embargo, en España aumentará la mortalidad por cáncer de pulmón en mujeres. Los resultados se publican en la revista Annals of Oncology.